Trial Profile
A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Per Oral Doses (15, 30, 40 µg Free Cation) BI 1744 CL in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record